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Patient A.S. (UPN 26) Patient M.L. (UPN 45) Patient E.M. (UPN 18)
A1Io-BMT - 8.11.1994 Allo-BMT -15.11.1996 Allo-BMT - 24.08.1993
CML FISH RT- Chimerism* CML FISH RT- Chimeris FISH CML FISH RT- Chimeris
Bcr-abl (+) PCR Bcr- PCR m* X, V Bcr-abl PCR m*
abl (+) (+)
Relapse Relapse Relapse
11.03.99 07.10.98 01.02.00
16.03.99 50% Recipient's 20.10.98 60-80% R 08.02.00 9,9% Mixed
genotype
12-24.03.99 21.10.98 29.02.00 23,1% Recipient's
HU OLiI genotype
24.03.99 HU lOll Mixed
-11.01.00 7.10-5.11.98 14.03.00
INF-alfa
28.10.99 2,92% b3a2 100%0 INF-alfa 12.04.00 37,3% b3a Mixed
02.11.- 2
02.12.98
04.11.99 b3a2 18.01.99 b2a2 60-80 % R 26.04.00 51,3%
16.02.00 2% 01.03.99 b2a2 20-40 % R II OLi
05.05.00
14.06.00 100%0 23.03.99 b2a2 10-20 % R 06.06.00 2,2% b3a Mixed
2
27.06.00 100%0 29.03.99 2% b2a2 100%0 04.07.00 b3a 100%0
2b2
a2
26.07.00 100 % 0 19.04.99 20% b2a2 100%0 23% 10.08.00 100 %0
21.04.99 23% XX
77%
XV
lOLl 100%0 05.07.99 17% b2a2 100%0 14.11.00 b2a 100%0
28.06.00 2
30.08.00 3% 100%0 22.09.99 6% b2a2 100%0 8% XX 10.01.01 b3a
2b2
a2
07.12.00 0% b2a2 100 % 0 28.09.99 b2a2 07.02.01 b3a
2
25.04.01 22% b2a2 22.12.99 5% b2a2 09.04.01
26.06.01 10% b2a2 29.03.00 1,97% b2a2 100%0 27.06.01 100% 0
28.08.01 21% b2a2 100%0 06.06.00 b2a2 100%0
29.09.01 10% b2a2 06.09.00 0% - 100%0 100%
XV
30.11.00 b2a2 100% 0
03.01.00
-
100%0
22.03.01 0% b2a2 100 % 0 100%
XV
12.09.01 7% b2a2 100 %0
09.11.01 23% b2a2 100%0 77%
XV
* examinations of chimerism status with
the use of STR-PCR were performed
without recipient's control sample before
BMT.
Conclusion: Combined evaluation
of the minimal residual disease by FISH,
RT-PCR and hematopoietic chimerism
by STR-PCR method gives more
informative details concerning response
to adoptive immunotherapy in post-
transplant relapsed CML patients with
BCR/ABL fusion gene.
This work was supported by the State
Committee for Scientific Research -
Projects NO.4 P05E 07419, No.6 P05E
035 20 and No 4 P05E 108 18.
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EXCEPT FOR TREOSULFAN AND
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A. Zaucha-Pratmo4
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Background and Objective: Results
of hematopoietic stem cell transplantation
(HSCT) in childhood acute leukemias,
are still unsatisfactory, however better
than obtained with conventional
chemotherapy. Probability of long-term
survival after HSCT is still only 40% - 50%.
The main cause of failure remains relapse
of the disease. Current possibilities
to augment an antileukemic effect
of HSCT include: protection of GvHD
and introduction of adoptive immuno-
therapy combined with the results of mo-
lecular chimerism and minimal residual
disease. Another possibility is the use
of more intensive or tailored preparative
regimen (prep-reg) before HSCT and mo-
dulation of drug resistance of residual
leukemic cells against agents used
in prep-reg. The aim of the study
is the analysis of in vitro drug resistance
profile in aspect of leukemia relapse after
HSCT.
Patients and Methods: A total number
of 22 children with acute leukemia
(14 ALL, 8 AML), aged 1,9-17 years, who
underwent HSCT, were included into
the study. For all children, drug resistance
profile was done by the MTT assay.
Leukemic cells of each child were tested
for cytotoxicity of up to 26 drugs (busulfan
and melfalan was not tested). Children
who have died due to peritransplant
complications were excluded from the stu-
dy. In 13 children HSCT was performed
from HLA identical sibling, in 2 from MUD,
in 1 from MMRD and 6 children had
autotransplantation. 8/22 children relapsed
after HSCT. Drug resistance profile was
performed in Laboratory of Clinical and
Experimental Oncology in Bydgoszcz.
The cytotoxicity was expressed
as the concentration of drug, which was
lethal to 50% of tested blasts. Children
with ALL were prepared to HSCT with:
FTBI/vP±CY (6 patients) or BU/vP/CY
(8 patients). Before MUD-HSCT, ATG was
also given. AML children were conditioned
with one the following sets of drugs:
BU/vP/CY, BU/CY/MEL, BU/CY, BU/MEL,
TREONP/CY, TREO/FLU/ATG, TREIFLU/MEL.
Results: Children who relapsed after
HSCT showed higher in vitro resistance
of leukemic blasts to most of tested drugs
including cyclophosphamide (3,3-fold) and
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fludarabine (2,3-fold). Only for 4/26 tested
drugs chemosensitivity of relapsed pa-
tients was better, i.e.: to treosulfan
(4,8-fold), etoposide (1,7-fold), thiotepa
(4,6-fold) and mercaptopurine (1,7-fold)
(all differences did not reach statistical
significance). 5/6 children prepared with
FTBI stays in remission.
Conclusions: The results of this ana-
lysis might suggest that relative sensitivity
of leukemic blasts to treosulfan and eto-
poside is not sufficient to prevent patient
from relapse after HSCT. This study give
an advantage for the use of cyclo-
phosphamide and FTB! in pre-reg,
however this observations require further
investigations.
This work was supported by grant
0501-1-05-30.
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TREOSULFAN WITH FLUDARABINE
AND MELPHALAN AS CONDI-
TIONING REGIMEN FOR SECOND
ALLOGENEIC BMT IN A CHILD
WITH POST-TRANSPLANT MDS
RELAPSE RESISTENT TO ADOP-
TIVE IMMUNOTHERAPY - A CASE
REPORT
J. Wachowiak\ M. Leda1, A. Pieczonka\
J. Styczynski 1 , D. Boruczkowski 1 ,
J. J6fkowska2 , M. Wite
1 HSCT Unit CIC 641, Institute
of Pediatrics, Poznan, 2 Institute of Human
Genetics, Poznan
We report a 10-year old girl with a dia-
gnosis of myelodysplastic syndrome, who
after first bone marrow transplantation
(HLA -matched sibling donor - May 1999)
suffered from relapse (Dec 2001) and
subsequently was treated by donor
lymphocyte infusions (twice) with no res-
ponse. We decided to perform a second
transplantation from the same donor but
with the use of different conditioning
regimen. It consisted of: treosulfan
(10 g/m2/day for 3 days, fludarabine
(30 mg/kg/day for 5 days) and melphalan
(140 mg/kg/day single dose). On day "0,,
(30 May 2001) she was infused with bone
marrow from her 8-year old, HLA-identical
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